吉崎 崇仁 (ヨシザキ タカヒト)

Yoshizaki, Takahito

写真a

所属(所属キャンパス)

医学部 内科学教室(神経) (信濃町)

職名 (名誉教授授与大学名)

専任講師(有期) (Assistant Professor)

研究室住所

新宿区信濃町35

研究室電話番号

03-5363-3788

 

論文 【 表示 / 非表示

  • Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?

    Funaki K, Tabuchi H, Yamagata B, Ito D, Yoshizaki T

    Psychogeriatrics, 2019年

    研究論文(学術雑誌), 共著, 査読有り

  • The psychological impact of disclosing amyloid status to Japanese elderly: A preliminary study on asymptomatic patients with subjective cognitive decline

    Wake T., Tabuchi H., Funaki K., Ito D., Yamagata B., Yoshizaki T., Kameyama M., Nakahara T., Murakami K., Jinzaki M., Mimura M.

    International Psychogeriatrics (International Psychogeriatrics)  30 ( 5 ) 635 - 639 2018年05月

    ISSN  10416102

     概要を見る

    © 2018 International Psychogeriatric Association. In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.

  • Advantages of Staged Angioplasty in a Patient with Internal Carotid Artery Pseudo-Occlusion Besides Prevention of Cerebral Hyperperfusion Syndrome

    Takahashi S., Akiyama T., Nakahara J., Yoshizaki T., Suzuki N., Yoshida K.

    World Neurosurgery (World Neurosurgery)  109   409 - 412 2018年01月

    ISSN  18788750

     概要を見る

    © 2017 Elsevier Inc. Background Staged angioplasty for carotid artery stenosis has been reported to be effective in preventing postoperative cerebral hyperperfusion syndrome (CHS) in patients with severe carotid stenosis; thus, it is also recommended for patients with internal carotid artery (ICA) pseudo-occlusion, the treatment strategy for which is controversial. Case Description This study reports the case of an Asian man in his 50s who had motor aphasia and right-side weakness caused by pseudo-occlusion of the left ICA. After medical treatment, he underwent a staged angioplasty. After the first stage of percutaneous transluminal angioplasty, anterograde blood flow to the left ICA increased but the distal ICA remained partially collapsed. Initially, the second stage of carotid artery stenting (CAS) was planned for 2 weeks after the first stage; however, hemorrhagic infarction was observed the day before the CAS, and it was postponed by 2 weeks, after adjustment of antiplatelet therapy. At the time of the CAS, the diameter of the initially collapsed left distal ICA was remodeled and it was fully dilated; thus, we used a balloon-type embolic protection device and conducted CAS successfully without apparent embolic complications. The postoperative course was uneventful. The patient did not develop CHS. Conclusions Besides preventing CHS, staged angioplasty has advantages when used for treating patients with ICA pseudo-occlusions in that the extent of dilation of the distal ICA after percutaneous transluminal angioplasty can be confirmed and the development of a possible hemorrhagic infarction can be assessed before stent placement.

  • The Efficacy and Safety of Yokukansankachimpihange for Treating Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: An Open-Label Pilot Study.

    Arita R, Yoshino T, Ohgishi M, Hamaguchi T, Horiba Y, Sawai K, Funaki K, Tabuchi H, Oka M, Yoshizaki T, Watanabe K, Mimura M,

    Advances in Alzheimer's Disease 7   141 - 152 2018年

    研究論文(学術雑誌), 共著, 査読有り

  • Extremely low prevalence of amyloid positron emission tomography positivity in Parkinson's disease without dementia

    Mashima K., Ito D., Kameyama M., Osada T., Tabuchi H., Nihei Y., Yoshizaki T., Noguchi E., Tanikawa M., Iizuka T., Date Y., Ogata Y., Nakahara T., Iwabuchi Y., Jinzaki M., Murakami K., Suzuki N.

    European Neurology 2017年06月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  00143022

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

研究発表 【 表示 / 非表示

  • 胚性幹細胞より誘導されたドーパミン作動性ニューロンのパーキンソン病モデルラットへの移植

    '吉崎崇仁, 稲次基希, 辻俊幸, 島崎琢也, 澤本和延, 安東潔, 須原哲也, 岡野 栄之'

    第18回神経組織の成長・再生・移植研究会学術集会 (東京) , 2003年06月, 口頭(一般)

 

担当授業科目 【 表示 / 非表示

  • 生理学Ⅰ

    2019年度

  • 内科学(神経)講義

    2019年度

  • 内科学講義

    2019年度